---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-178827"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2024-07-15T23:59:59+00:00"
generated_at: "2026-05-31T20:42:37.442016+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences enters $60M ATM equity facility; prelim Q2 net loss $10.7-12.7M

## Summary
- Up to $60M at-the-market offering via Canaccord Genuity and Needham; commission up to 3%.
- Preliminary Q2 2024 cash and cash equivalents $26.0-26.5M (excl. $60M rights offering close in July).
- GAAP net loss $10.7-12.7M; non-GAAP net loss $8.7-9.7M.
- GAAP costs and expenses $11-13M; non-GAAP costs $9-10M; adjustments include stock-based comp and D&A.

## SEC filing metadata
- accession: 0001193125-24-178827
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2024-07-15T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000119312524178827/0001193125-24-178827-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000119312524178827/d867904d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-178827
- JSON: https://secwatch.observer/filing/0001193125-24-178827.json
- Plain text: https://secwatch.observer/filing/0001193125-24-178827.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.